

NC Medicaid Pharmacy Prior Approval Request for

Migraine Calcitonin Agents: Preventative-Aimovig/Ajovy/Emgality/Vyepti/Qulipta/Nurtec

Beneficiary Information

1. Beneficiary Last Name:	2. First Name:	
3. Beneficiary ID #:	4. Beneficiary Date of Birth:	5. Beneficiary Gender:

Prescriber Information

6. Prescribing Provider NPI #: ______ 7. Requester Contact Information - Name: ______ Phone #: ______ Ext. _____ Address_____

Drug Information

8. Drug Name:	9. Strength:	10. Quantity Per 30 Days:
11. Length of Therapy (in days):	□ 60 Days □ 90 Days □ 120 Day	<i>ı</i> s □ 180 Days □ 365 Days

Clinical Information

Initial authorization for PREVENTATIVE treatment of Migraines (INJECTABLES) (Aimovig, Ajovy, Emgality 120mg/ml, and Vyepti) **Initial requests can be approved for up to 3-months for Aimovig, Emgality, Ajovy, and Vyepti for monthly dosing or up to 6 months for Ajovy quarterly dosing**:
 Does the beneficiary have a diagnosis of migraine with or without aura based on International Classification of Headache Disorders criteria?
2. Is the beneficiary 18 years old or older? Yes No
3. Does the beneficiary have medication over-use headache (MOH)? □ Yes □ No
4. For beneficiaries that are women of childbearing age, is there a negative pregnancy test at baseline? Yes No
5. Has the beneficiary experienced 4 or more migraine days per month for at least 3 months? 🗆 Yes 🗆 No
6. Is the beneficiary utilizing prophylactic intervention modalities (e.g. behavioral therapy, physical therapy, life-style modifications)?
7. Has the beneficiary tried and failed at least a month or greater trial of medications from at least 2 different classes from the following list of oral medications: 1. Antidepressants (e.g. amitriptyline, venlafaxine) 2. Beta Blockers (e.g. propranolol, metoprolol, timolol, atenolol) 3. Anti-epileptics (e.g. valproate, topiramate) 4. Angiotensin converting enzyme inhibitors/angiotensin II receptor blockers (e.g. lisinopril, candesartan) 5. Calcium Channel Blockers (e.g. verapamil, nimodipine)? I Yes I No Please list medications tried:
Initial authorization for PREVENTATIVE treatment of Migraines (ORALS) (Nurtec ODT, Qulipta) **Initial requests can be approved for up to 3-
months
1. Does the beneficiary have a diagnosis of migraine with or without aura based on International Classification of Headache
Disorders criteria? Yes No
2. Is the beneficiary 18 years old or older? Yes No
3. Does the beneficiary have medication over-use headache (MOH)? Yes No
4. Has the beneficiary experienced 4 or more migraine days per month for at least 3 months? Yes No
5. Is the beneficiary utilizing prophylactic intervention modalities (e.g. behavioral therapy, physical therapy, life-style modifications)?
 Has the beneficiary tried and failed at least 2 preferred injectable CGRPs? □ Yes □ No For Nurtec ONLY
7a. Will the Beneficiary use Nurtec concurrently with a strong CYP3A4 inhibitor? 🗆 Yes 🗆 No
7b Does the Beneficiary have end-stage renal disease with a creatinine clearance (CrCl) less than 15ml/min? 🛛 Yes 🗆 No
Initial authorization for treatment of Episodic Cluster Headache in Adults (Emgality 100mg/ml) **Initial requests can be approved for up to 3-
months**:
1. Does the beneficiary have a diagnosis of Episodic Cluster Headache? □ Yes □ No 2. Has the beneficiary experienced 2 cluster periods lasting from 7 days to 1 year (when treated) and separated by pain-free
remission periods of at least 3 months? Yes I No
3. Is the beneficiary 18 years old or older? \Box Yes \Box No
4. For beneficiaries that are women of childbearing age, is there a negative pregnancy test at baseline? \Box Yes \Box No
5. Is the beneficiary utilizing prophylactic intervention modalities (e.g. medication therapy)? \Box Yes \Box No
 6. Is the beneficiary receiving no more than 300mg (administrated as three consecutive injections of 100mg each) at the onset of the cluster headache period and then monthly until the end of the cluster headache period?



NC Medicaid Pharmacy Prior Approval Request for

For re-authorization for all diagnoses **Re-authorization requests can be approved for up to 12 months**:

1. Has the beneficiary experienced a significant decrease in the number, frequency, and/or intensity of headaches and/or decrease in the length of the cluster period?
I Yes
No

2. Has the beneficiary experienced an overall improvement in function with therapy?

Yes
No

3. Does the beneficiary continue to utilize prophylactic intervention modalities (e.g. behavioral therapy, physical therapy, life-style modifications)?

Yes
No

4. If the beneficiary is a woman of childbearing age, is the provider continuing to monitor for pregnancy status? (not required for Qulipta or Nurtec) □ Yes □ No

5. Is the beneficiary experiencing unacceptable toxicity (e.g. intolerable injection site pain, constipation)? 🗆 Yes 🗆 No

Signature of Prescriber:

Date:

(Prescriber Signature Mandatory) I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.